Featured Speakers

• 

  Jeff DageSenior Research Advisor Eli Lilly

• 

  Sandra EngleSenior Principal Scientist, Pluripotent Stem Cell Biology Pfizer

• 

  Rudolf JaenischProfessor of Biology & Founding Member MIT & The Whitehead Institute

• 

  Lee RubinProfessor, Stem Cell & Regenerative Biology Harvard University

Advances in stem cell research are pulling drug developers together under one roof...

The opportunities that iPSCs and ESCs offer to drug discovery and development are enormous: Modeling diseases which have complex genetic basis; novel indicators of drug efficacy and safety; more effective toxicological testing; drug screening in specific genotypes. And implemented correctly these advances will arm you with the tools you need to develop innovative drugs and bring them to the clinic faster, saving you time and money.

But what approaches are currently being used to successfully generate uniform populations of iPSC/ESC derived cells? And how can you incorporate stem cells into drug discovery and development to understand the mechanism of action of drug induced toxicities?

In designing the agenda, we’ve spoken to pharma/biotech companies like AstraZeneca, GSK, Pfizer, AVEO Pharmaceuticals and leading academics from Harvard University, The Wyss Institute and The Buck Institute among others. People already developing and using stem cell-derived models.

The 2nd Stem Cells for Drug Developers meeting will bring together world leading experts from industry and academia to tackle the practical and scientific issues of developing stem cell-derived models.Learn, network and discuss: Harness the full potential of stem cells and improve your R&D process and pipeline efficiency.

What will be covered on the agenda?

• Understand the scientific mechanisms that control stem cell differentiation to generate homogenous cell populations which maintain the disease phenotype

• Examine whether iPS cells can be a valid substitution for ESCs and what their applications are for safety/tox testing

• Discuss strategies to promote full maturation of stem cell-derived cell populations and advance your research efforts

• Overcome challenges in stem cell production to make sufficient numbers for drug development

• Learn new approaches to achieve validation of your assay

• Harness the potential that iPS cells offer for individualized safety & efficacy screening

And much more, click here to download the final agenda.

Why attend?

• The 2nd Stem Cells for Drug Developers meeting address will address the current scientific and practical barriers and discuss new opportunities to revolutionize your drug development process using stem cells

• Meet and network with scientists leading the field from pharma and academia, and leave the meeting with an array of new ideas and contacts to take back to your organization

For more information on what will be covered in the meeting, simply download the final agenda by clicking here. To secure your place and take advantage of the early registration rates, book your place now.